James R. Kasinger
2021
In 2021, James R. Kasinger earned a total compensation of $4.6M as General Counsel at CRISPR Therapeutics AG, a 79% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $229,500 |
|---|---|
| Option Awards | $2,771,741 |
| Salary | $425,000 |
| Stock Awards | $1,204,920 |
| Other | $11,600 |
| Total | $4,642,761 |
Kasinger received $2.8M in option awards, accounting for 60% of the total pay in 2021.
Kasinger also received $229.5K in non-equity incentive plan, $425K in salary, $1.2M in stock awards and $11.6K in other compensation.
Rankings
In 2021, James R. Kasinger's compensation ranked 2,849th out of 12,415 executives tracked by ExecPay. In other words, Kasinger earned more than 77.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,849 out of 12,415 | 77th |
Division Manufacturing | 1,132 out of 5,505 | 79th |
Major group Chemicals And Allied Products | 450 out of 2,375 | 81st |
Industry group Drugs | 394 out of 2,096 | 81st |
Industry Biological Products, Except Diagnostic Substances | 115 out of 449 | 74th |
Source: SEC filing on April 25, 2022.
Kasinger's colleagues
We found five more compensation records of executives who worked with James R. Kasinger at CRISPR Therapeutics AG in 2021.
2021
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
2021
Brendan Smith
CRISPR Therapeutics AG
Chief Financial Officer
2021
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
2021
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
2021
Michael Tomsicek
CRISPR Therapeutics AG
Chief Financial Officer
News
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
April 25, 2022
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2020 pay falls 44% to $9.1M
April 28, 2021
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2019 pay jumps 67% to $16M
April 24, 2020
CRISPR Therapeutics AG CEO Samarth Kulkarni's 2018 pay jumps 40% to $9.7M
April 30, 2019